Impact of an evolving regulatory landscape on skin cancer drug development in the U.S.
Miller David M, Shalhout Sophia Z, Casey Denise, +4 more·Dermatology online journal
BACKGROUND: There has been a rapid proliferation of FDA-approved medications with labeled indications for skin cancer over the last decade, with particular growth over the last 5 years. OBJECTIVE: We aimed to evaluate the impact of an evolving U.S. regulatory framework on drug development programs to better understand…